In this regard, it is known that sodium-glucose cotransporter-2 inhibitors (SGLT2is) significantly improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM) and in non-diabetic patients with heart failure [135,136]. Here, SLC5A2 is linked to type 2 diabetes mellitus.